Glycoprotein IIb/IIIa inhibitors
From Wikipedia, the free encyclopedia
In medicine, a glycoprotein IIb/IIIa inhibitors, also GpIIb/IIIa inhibitors, is class of antiplatelet agents.
Several GpIIb/IIIa inhibitors exist:
- abciximab (ReoPro®)
- eptifibatide (Integrilin®)
- tirofiban (Aggrastat®)
[edit] Use
Glycoprotein IIb/IIIa inhibitors are frequently used during percutaneous coronary interventions (angioplasty with or without intracoronary stent placement).
They work by preventing platelet aggregation and thrombus formation. They do so by inhibition of the GpIIb/IIIa receptor on the surface of the platelets.
[edit] History
Their development arose from the understanding of Glanzmann's thrombasthenia, a condition in which the GpIIb/IIIa is lacking.[1]
[edit] Reference
- ^ Seligsohn U. Glanzmann thrombasthenia: a model disease which paved the way to powerful therapeutic agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):216-7. PMID 13679645. Free Full Text.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
